Taylor Corbitt

Partner ( Chicago )

Direct 312.471.8670 Fax 312.471.8701 LinkedIn

Bio

Taylor Corbitt concentrates her practice in intellectual property litigation and patent litigation covering a wide variety of technologies, with a particular emphasis on high-tech and pharmaceutical/ biotechnology.  She also provides counseling and change-management consulting services for corporate legal departments in transition, and she recently completed nearly a year serving as Interim Head of Worldwide Litigation for a Global 200 technology company.  

Taylor has a unique understanding of the entire IP “life cycle,” from planning and procurement through enforcement and monetization. Her experience over a decade of patent practice includes portfolio planning and counseling, patent prosecution, clearance and freedom-to-operate opinions, IP due diligence for corporate mergers and acquisitions, pre-litigation analysis, proceedings before the Patent Trials and Appeal Board of the U.S. Patent and Trademark Office, and all aspects of patent litigation.

Taylor also represents clients in patent litigation concerning technologies related to medical devices, consumer products, and mechanical devices.  She has been named an “Emerging Lawyer” in the fields of both Intellectual Property Law and Patent Law by Law Bulletin Publishing Company’s Leading Lawyers from 2015-2018.

Experience

 Recent Engagements

  • Obtained summary judgment of infringement of asserted mechanical device patent for the plaintiff/patentee.
  • Obtained multiple dismissals of non-practicing entity patent infringement claims directed to computer method technology as invalid for failure to claim patent-eligible subject matter.
  • Secured multiple favorable pretrial settlements for generic pharmaceutical products accused of patent infringement, including early market entry for generics.
  • Secured multiple injunctions, lost-profits reimbursement, and dismissals with orders that a competitor go off-market for client in the medical device market.
  • Obtained transfer of venue in patent litigation matter from Eastern District of Texas to Defendant’s home forum, followed by an early settlement of non-practicing entity patent infringement claim in consumer products case.
  • Consulted on drug formulation and development, pre-litigation opinions and regulatory counseling for a global healthcare and pharmaceutical company.
  • Obtained discovery sanctions, including adverse inference and order compelling foreign national and CEO of China-based company to appear for deposition in client/defendant’s home district.
  • Managed prosecution, counseling, opinion, and portfolio management engagements, including: conducted trademark prosecution and counseling for a worldwide trademark portfolio; IP counseling and portfolio development for a mid-sized insurance and managed care company; and managed international patent prosecution and counseling for two high-priority drug portfolios for a Fortune 100 drug company.

Credentials

Education

DePaul University College of Law, J.D., 2009, Member, Journal of Art, Technology and Intellectual Property Law

University of Virginia, B.A., Molecular Biology, Music, 2006

Bar Admissions

Illinois
U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the Northern District of Illinois
U.S. District Court for the Eastern District of Wisconsin
U.S. Patent and Trademark Office

Honors & Awards

Emerging Lawyer in Intellectual Property Law and Patent Law, Law Bulletin Media Leading Lawyers (2015-2018)

Publications & Presentations

“Strategic Patent Portfolio and Lifecycle Development for Pharma & Biotech Industries,” (webcast speaker) The Knowledge Group (January 12, 2017)

“Identifying and Leveraging Trade Secret Claims in Commercial Litigation Post-DTSA,” (copresenter) CBA Commercial Law Section (September 28, 2016)

“Myriad Faces Yet Another Patent Eligibility Battle In Return to the Federal Circuit,” Schiff Hardin Client Alert (October 8, 2014)

“A Look At Abbott's Citizen Petition Against The Biologics Price Competition And Innovation Act,” PharmaPatents Blog guest post (June 28, 2012)

“The Pharmaceutical Frontier: Extending Generic Possibilities to Biologic Therapies in the Biologics Price Competition and Innovation Act of 2007,” 18 DePaul J. Art, Tech. & Intell. Prop. L. 365 (2008)

Numerous publications for RSHC “State of the Art” patent blog, including:

  • Supreme Court Limits Post-Sale Patent Rights (June 2017)
  • Supreme Court Abolishes Laches Defense in Patent Cases (March 2017)
  • Federal Circuit Clarifies the Boundaries of the Elusive “Abstract Idea” in Section 101 Challenges (September 2016)